ASX 200

Read on to find the ratings, consensus price targets, and FNArena insights on each stock covered.

And four narratives that will be tested this reporting season...

We look at five of the biggest developments across global markets for the week ending 9 August 2024

It's been labelled an "incredible business" and an ASX "market champion". But can REA Group surpass the lofty earnings expectations?

Despite challenges like inflation and finance costs, Transurban will retain its position in The Montgomery Fund’s portfolio.

Are these ASX companies the investing equivalent to some of the world's great Olympians? I'll take a look.

There are several pieces of credible evidence to support the case for a price bounce, which would be good news for fast-growing Patriot.

In this episode, Marcus Today's Henry Jennings and Market Matters' James Gerrish analyse some of the market's hottest growth stocks.

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.

In this episode of The Pitch, gold expert Robin Tsui from State Street Global Advisors answers investors most common questions on gold.

Ausbil's Arden Jennings shares his Australian small and micro-cap stock tips to outperform in the coming years.

From "Rocky" in Queensland to investment management royalty. In this episode, Pinnacle Founder Ian Macoun shares his miraculous story.

There are signs of life for small-cap investors. Here's how Oscar Oberg is positioning the Wilson Asset Management portfolios.

If you want to ‘win’ (maybe termed ‘beating the average’) at investing, and protect your hard-earned capital, position sizing is the secret.

We delve into the case for prioritising Value for a pathway beyond the current market conditions.

From digging for unloved value to discovering the best founder-led companies, these investors have different views on how to generate alpha.

The most important month of the investing year is here - and the stakes are very high.

ResMed (ASX:RMD) reported its June quarter and full year results after the U.S. market closed on Friday morning. The company met consensus expectations for both...

Find out in this episode of Buy Hold Sell - featuring Henry Jennings from Marcus Today and James Gerrish from Market Matters.

ASX Reporting Season begins with Rio Tinto and ResMed surging. The RBA may pause rate hikes after lower inflation. Fed hints at rate cuts.

It's been a wild ride for ResMed over the past couple of years and while there might be further volatility, things are back on track

And why it's the points that you win that matter.

As BHP/Lundin lock in their South American prize, former geologist, James Cooper discusses the opportunity cost for junior mining investors

Metro says prices are surging. And now Flanagan’s Arrow has secured a big bauxite project; $9m Gateway pockets $14m from sale to Brightstar.